Fungal infections, also known as mycoses, are eitherare either superficial or invasive into vital organs, such as the lungs, brain, and blood, and, in most cases, cause death. The burden of invasive fungal diseases worldwide is high, with an estimated 6.75 million cases and about 3.8 million deaths every year, with many of these directly related to fungal infection. Due to the increase in the number of immunocompromised, such as cancer, diabetes, or receiving immunosuppressive treatment, there has been an increased need for systemic antifungal therapy butstill, mortality rates remain high, with some invasive fungal infections having mortality rates exceeding 40%–70%, based on the pathogen and patient population.¹ The surveillance data show that the incidence of yeast fungemia and other invasive fungal diseases is slightly rising and that the remaining diseases are not decreasing, with older patients having a higher incidence.² The prevalence of invasive fungal infections among critically ill patients is pooled at the levels of 5% with Candida and Aspergillus species, leading to substantial prevalence and mortality rates, despite the improvements in diagnostics and effective treatment of these infections. These results indicate a dire need to come up with better prevention, early diagnosis, and management strategies to curb the worldwide health burden of invasive fungal diseases.¹

First-generation triazole Fluconazole (approved 1990) was the first oral agent to be used as treatment of fungi; it was an effective agent due to its high oral bioavailability (>90%), low protein affinity, and wide tissue distribution, including approximately 80% cerebral penetration into cerebral spinal fluid (CSF) in cryptococcal meningitis.^3,4 Its action is selective inhibition of lanosterol 14-alpha-demethylase that impairs the ergosterol synthesis needed in cell membrane integrity of fungi, causing fungal death with the least toxicity to the human cell. Fluconazole is mainly excreted by the kidneys, so the dosage has to be increased in patients with renal failure or under dialysis. Its half-life is long, which enables easy dosages to be administered.⁵ Nevertheless, the clinical utility of fluconazole is now facing an increasing threat due to emerging antifungal resistance, particularly in Candida parapsilosis and Cryptococcus neoformans, which is frequently associated with genetic mutation, including ERG11 gene mutation and aneuploidy of chromosomes, which makes the treatment of the disease more difficult.⁶ Development of resistance is especially troublesome with cryptococcal meningitis, where monotherapy of fluconazole demonstrates poor results, owing to the development of dynamic resistance, with only a minimal proportion of patients achieving sterility of their CSF, even with high doses (1200 mg/day), and some resistant subpopulations remaining.⁵ To address these problems, antifungal stewardship, maximized dose regimens, combination therapy, and the investigation of novel antifungal agents such as posaconazole and rezafungin, which are active against resistant strains and have the potential to enhance the clinical outcome, are essential.⁶

The electronic databases, such as PubMed, Scopus, and Google Scholar, were used to find pertinent material published between 2000 and 2025 for this narrative review. Using Boolean operators (AND, OR) in conjunction with terms like “fluconazole,” “antifungal resistance,” “pharmacokinetics,” “candidiasis,” and “cryptococcosis,” a thorough search strategy was implemented to narrow down the search results. Based on predetermined inclusion and exclusion criteria, studies were chosen. Peer-reviewed publications, clinical trials, systematic reviews, and meta-analyses that concentrated on the pharmacological characteristics, clinical effectiveness, and resistance mechanisms of fluconazole were among the inclusion criteria. Studies offering molecular insights into antifungal resistance were also considered. Non-English publications, duplicate records, conference abstracts without complete data, and research without full-text access were among the exclusion criteria. To guarantee therapeutic relevance, pertinent clinical practice guidelines from groups like the IDSA (Infectious Diseases Society of America) and the ECMM (European Confederation of Medical Mycology) were also incorporated.^7,8 To ascertain eligibility, all identified papers were first screened using titles and abstracts, and then their entire texts were examined. To guarantee the inclusion of current evidence, preference was given to recent, high-quality, and clinically significant studies.

The triazole antifungal drug fluconazole works by specifically blocking the fungal cytochrome P450 enzyme lanosterol 14-α-demethylase, which is produced by the ERG11 gene. The formation of ergosterol, a crucial structural element of the fungal cell membrane, depends on the demethylation of lanosterol, which is catalyzed by this enzyme. Toxic 14-methyl sterol intermediates build up, and ergosterol is depleted when lanosterol 14-α-demethylase is inhibited. These changes impede the function of membrane-associated proteins and enzymes, compromise membrane integrity, and increase membrane permeability, all of which eventually prevent fungal growth. Although fungicidal effects may occur at greater concentrations against susceptible species like Candida albicans, fluconazole primarily demonstrates fungistatic activity. These effects have been linked to increased production of reactive oxygen species (ROS), intracellular metacaspases, and mitochondrial malfunction, all of which contribute to fungal cell death. Crucially, fluconazole exhibits selective toxicity because it has a greater affinity for fungal cytochrome P450 enzymes than its mammalian counterparts, which reduces its effects on host cells (Table 2).²⁴

Fluconazole resistance is a growing problem in Candida spp. and Cryptococcus neoformans, driven by several well-defined molecular and cellular adaptations.

Fluconazole is a bis-triazole antifungal agent that has good pharmacokinetic properties, such as high-water solubility, metabolic stability, and good tissue penetration; therefore, it can be used to treat various fungal infections, including oropharyngeal, esophageal, and disseminated candidiasis, with clinical response rates ranging between 50%–90%. It also works well in cryptococcal meningitis, especially combined with amphotericin B therapy, with such a combination giving equal levels of clinical response and relapse prevention.³¹ Fluconazole has been frequently used as prophylaxis in immunocompromised patients receiving chemotherapy or bone marrow transplantation, in lowering the frequency of oral fungal infections and invasive candidiasis, and in low-dose regimens, similar effectiveness and safety have been observed as in higher doses.³² Fungistatic, not fungicidal, but easy to administer in either oral or intravenous form, fluconazole is typically better tolerated than other antifungals. Once-daily dosing is convenient, and it is being used in Candida glabrata and Cryptococcus neoformans, but resistance is a problem in Candida glabrata. Its merits are high patient compliance, mild side effects, and a wide range of usability in both prophylaxis and treatment; however, its demerits are that it may cause relapses in immunocompromised patients, it is potentially hepatotoxic, and it exhibits less effectiveness against resistant strains, forcing close clinical usage and observation.³³ In general, fluconazole has become an important antifungal agent with proven clinical efficacy, especially in the treatment of candidiasis and cryptococcosis (Figure 2), but the use of these drugs should be adjusted to the susceptibility patterns and patient risk factors in order to maximize the effect.³⁴

The following are the common adverse drug reactions with fluconazole: gastrointestinal, skin reactions, xerosis, alopecia, and fatigue, with a number of patients experiencing mild to moderate effects, which occasionally necessitate a reduction in dose or discontinuation, particularly in long-term use. Hepatotoxicity is another significant issue, as there have been increased liver enzymes in both adults and children, though the majority of cases will heal fully when monitored and dose-regulated; drug interactions may result in more liver toxicity and should be considered carefully. Fluconazole, which is commonly used for chronic fungal infections, has a greater rate of adverse effects, especially fatigue and skin problems, and approximately two out of every three infected individuals may require therapeutic modification. Serious but infrequent adverse events are neurotoxicity and cardiac conditions, such as changes in the QT interval and systemic reactions, which may be fatal and merit vigilance in treatment. Fluconazole is more tolerable than other antifungals and has a reduced percentage of therapy discontinuation because of adverse effects; however, it is important to monitor liver, kidney, and cardiovascular functions, particularly in high-risk groups and when administered over a long period. All in all, the safety of fluconazole is positive and needs continuous clinical observation to address hepatotoxicity, drug interactions, and infrequent severe adverse events to promote safe and effective use.³⁵

Fluconazole resistance is a growing issue worldwide, especially among Candida species, including Candida albicans, Candida glabrata, and Candida parapsilosis, whose resistance mechanisms encompass mutations in ergosterol biosynthesis pathways (e.g. ERG11), overexpression of efflux pumps, and biofilm formation, all of which contribute to decreased drug susceptibility.³⁶ Candida parapsilosis has been demonstrated to have significant resistance to fluconazole in the case of hospital outbreaks that are highly fatal, usually due to particular gene mutations, such as Y132F, and the development of resistance can occur even in patients who are new to azoles.³⁷ The heteroresistance mechanism of Cryptococcus neoformans is a survival of subpopulations at increased drug levels, which is frequently caused by chromosomal disomy, overexpressing resistance genes, including ERG11 and AFR1, and making them more difficult to treat and linked to worse clinical outcomes.³⁸ The long-term and prophylactic treatment of fluconazole in immunocompromised patients facilitates the emergence of resistant strains due to the selective pressure caused by antifungal use, which causes the necessity of antifungal stewardship and the exclusion of alternative therapy. Surveillance evidence suggests that there is a gradual yet consistent growth in isolated cases of fluconazole-resistance around the globe, where regional disparities and the development of multidrug resistance represent a huge treatment challenge. On the whole, to control the spread of resistance to fluconazole, it is essential to comprehend the molecular resistance mechanism and track epidemiological trends to make effective clinical decisions.³⁷

Molecular processes of changing the targets of drugs, increasing the efflux of the drug, and modifying cell components are the main mechanisms of resistance to fluconazole among the most common pathogenic fungi. The major mutations are observed in the gene (ERG11) of the ergosterol-biosynthesis pathway, along with its regulator (UPC2), which decreases the ability to bind fluconazole and its activity.³⁹ Active expression of efflux pump genes (CDR1, CDR2, and MDR1), usually controlled by transcription factors (TAC1 and PDR1), actively extrudes fluconazole out of fungal cells and plays a role in resistance, particularly in Candida albicans and Candida glabrata.⁴⁰ Such a rapid adaptive response has been found to be aneuploidy, the acquisition of an additional chromosome that has resistance genes, which has increased fluconazole resistance by increasing the gene dosage.⁴¹ Other mechanisms are changes in the sphingolipid composition, which influence the membrane properties and drug susceptibility, and biofilm formation, which offers a sheltered environment against antifungals.³⁶ All these molecular adaptations demonstrate that resistance to fluconazole is a complicated issue and requires specific strategies to address it in different Candida types and other future pathogens such as C. auris.⁴²

The combinations of antifungal therapy, adjuvant agent use, derivatives of fluconazole, focusing on other ergosterol pathway sites, and antifungal stewardship programs are the strategies to overcome resistance to fluconazole. Synergies between combination therapies have been reported; for example, between fluconazole and curcumin nanosuspensions, iron chelators like deferasirox, and disrupting biofilms, thus regaining fluconazole activity against resistant Candida strains.⁴³ Delivery systems that utilize nanoparticles also cause a reduction in effective doses of fluconazole and resistance reversal by enhancing the bioavailability of drugs and by targeting a variety of resistance pathways.⁴⁴ Novel molecular pathways can be targeted to re-sensitize resistant strains to fluconazole, including the ATP-dependent unfoldase ClpX that is found in Cryptococcus neoformans, which provides new therapeutic opportunities.⁴⁵ The new antifungal agents that have different mechanisms of action, such as anti-ergsterol and anti-b-glucan biosynthesis, are under development in an effort to overcome resistance and toxicity problems of the available medications.³⁷ Lastly, antifungal stewardship measures are essential to reduce unwarranted use of fluconazole as well as to decrease the selective pressure and delay the occurrence of resistance, and natural substances, such as flavonoids and freshwater mussel extracts, have potential as adjuvants to increase fluconazole susceptibility and decrease fungal virulence.⁴⁶

Recent developments in the field of overcoming fluconazole resistance are oriented toward new research directions, new drug formulations, and use of personalized antifungal therapy. The resistance and toxicity of existing antifungal drugs are being countered by exploring new antifungal agents with novel mechanisms, including ergosterol and β-glucan biosynthesis antifungals, among others.²⁴ Nanosuspensions of curcumin and solid lipid nanoparticles that are designed in nanotechnology increase the effect of fluconazole in the treatment of persistent fungal biofilms by increasing solubility, bioavailability, and targeting biofilms.⁴³ The small molecules, such as the 1,4-benzodiazepines, have been found that can restore the fluconazole susceptibility in the resistant strains by enhancing drug efficacy and suppressing fungal virulence factors, and have potential in the systemic infection models.⁴⁷ Individualized antifungal treatment, informed by knowledge of individual resistance mechanisms; for example, mutation in Candida parapsilosis or the involvement of proteins like ClpX in Cryptococcus neoformans, could yield better treatment outcomes by directing drug selection and combinations. All in all, the combination of new formulas, specific therapies, and programs of stewardship is the overall future approach to handling the increasing challenge of fluconazole resistance.⁴⁸

Fluconazole is an antifungal agent, which is considered a cornerstone antifungal agent because of its good pharmacokinetics, high tolerability, and wide clinical applicability. It is especially useful in treating invasive and opportunistic infections caused by fungi, due to its capacity to attain a high bioavailability and reach critical locations, including the central nervous system. Nevertheless, the growing level of resistance among Candida species and Cryptococcus neoformans is an expanding issue. The mechanisms of resistance, such as ERG11 gene mutations, activation of efflux pumps, and adaptive stress responses, influence the efficacy and clinical outcomes of the treatment to a significant extent. These issues highlight the need to focus on proper dosing approach, therapeutic drug observation in special groups, and the rational application of antifungal agents. The future outlook would be the creation of new fluconazole derivatives, combination therapy, and new drug delivery systems like nanocarriers to increase antifungal efficacy and surmount resistance. Moreover, the concept of individual antifungal treatment, depending on pharmacokinetic–pharmacodynamic principles and pathogen-specific patterns of susceptibility, is prospective to enhance treatment outcomes. Surveillance and further research are needed to maintain the long-term efficacy of fluconazole in clinical practice.